Medication info
Mgliduo Extended-Release Tablet 25/1000 mg (Empagliflozin, Metformin Hydrochloride)

Mgliduo Extended-Release Tablet 25/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin Amorphous›25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceutical Co., Ltd.
Appearance
Pink rectangular extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501417 · Approved 2025.06.10 · Insurance code 663608940

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose of metformin hydrochloride gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the active ingredient of the medicine is present in material excreted in the stool. If a patient repeatedly reports finding this medicine in the stool, the healthcare provider should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's existing dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is administered concomitantly with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse reactions and 6. Interactions.) Special populations Renal impairment Because dose adjustment according to renal function is required, renal function should be assessed before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine must be discontinued immediately. Elderly In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Korea Prime Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Difficulty controlling blood sugar
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used to help control blood sugar in adults with type 2 diabetes who are also following dietary and exercise regimens. It specifically helps lower blood sugar effectively by administering empagliflozin and metformin together. It may also have some effect in adults with type 2 diabetes whose blood sugar is not well controlled and have cardiovascular disease, thus it is important to refer to professional guidance. This medication improves blood sugar management and assists in diabetes treatment.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose of metformin hydrochloride gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the active ingredient of the medicine is present in material excreted in the stool. If a patient repeatedly reports finding this medicine in the stool, the healthcare provider should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's existing dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is administered concomitantly with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse reactions and 6. Interactions.) Special populations Renal impairment Because dose adjustment according to renal function is required, renal function should be assessed before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine must be discontinued immediately. Elderly In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used for the treatment of diabetes and should not be used in patients with poor kidney function, acute infections, dehydration, or unstable heart function. It can rarely cause serious side effects such as lactic acidosis; thus, it is essential to inform a doctor immediately if symptoms such as muscle pain, breathing difficulties, weakness, or abdominal pain occur while taking this medication. The risk of hypoglycemia may increase when used with insulin or other blood sugar-lowering agents, thus careful monitoring of blood sugar changes is necessary, and medication dosage may require adjustment if needed. Urinary tract infections or genital infections may occur, so prompt treatment should be sought if any symptoms of infection appear. This medication may affect kidney function, making regular blood tests to monitor kidney status important. Moreover, it may lead to a decrease in fluid volume, and caution should be exercised by elderly patients or those with dehydration or low blood pressure. It is safest to avoid using this medication in pregnant women or those who may become pregnant, as well as in breastfeeding individuals. Patients scheduled for surgery or undergoing iodine contrast tests should temporarily discontinue the medication and resume it only after confirming normal kidney function. This medication should not be chewed or crushed and should be swallowed whole; the tablet coating may appear in the stools, but this is normal. In case of overdose, immediate medical attention should be sought, particularly because symptoms of lactic acidosis may occur. Excessive alcohol consumption should be avoided while taking this medication, and any unusual symptoms or suspected side effects related to the medication should be promptly discussed with healthcare professionals.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • nausea
  • vomiting
Show 164 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • urosepsis
  • pyelonephritis
  • headache
  • dizziness
  • insomnia
  • weight loss
  • constipation
  • gastritis
  • oral discomfort
  • salivary gland pain
  • sensory impairment
  • positional dizziness
  • amnesia
  • drowsiness
  • fatigue
  • peripheral edema
  • facial edema
  • fever
  • facial swelling
  • chills
  • strange sensations
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • urinary stones
  • hematuria
  • kidney mass
  • urinary retention
  • urinary pain
  • urinary abnormalities
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypercholesterolemia
  • dyslipidemia
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exercise-induced dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial obstructive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • diabetic foot

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, at room temperature between 1 to 30 degrees Celsius. Proper storage can maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Pink rectangular extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.